ResMed Inc (STU:RME)
€ 232.3 -1.9 (-0.81%) Market Cap: 34.52 Bil Enterprise Value: 34.92 Bil PE Ratio: 32.70 PB Ratio: 6.98 GF Score: 98/100

Resmed Inc at Goldman Sachs Global Healthcare Conference (Virtual) Transcript

Jun 08, 2021 / 05:20PM GMT
Release Date Price: €169.4 (+0.21%)
Chris Cooper
Goldman Sachs Group, Inc., Research Division - Research Analyst

Next up, we're very fortunate to be joined by Rob Douglas, the COO of ResMed. In a moment, I'll hand over to Rob and invite him to make some introductory comments. Please do, as we go through the session, please shoot me any questions that you may have via e-mail. My e-mail is [email protected]. If I don't manage to get to them through the session, I'll endeavor to follow-up with the company. This session is due to last about 40 minutes or so. We're going to try and keep it interactive. And I'll hand it over to Rob, and we'll go from there. Thanks, Rob.

Robert A. Douglas
ResMed Inc. - President & COO

Great. Thanks, Chris, and thank you, everyone, for joining. Just a few brief comments before we launch. The -- we reported our results about 4 weeks ago. And really, the story there is a sort of steady recovering new patient flow. The results were distorted versus last year as probably for many companies, given we had extremely unusual few quarters this time last year. But

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot